Photocure ASA
OSE:PHO

Watchlist Manager
Photocure ASA Logo
Photocure ASA
OSE:PHO
Watchlist
Price: 53.9 NOK 1.7%
Market Cap: 1.5B NOK

Operating Margin
Photocure ASA

3.9%
Current
-2%
Average
7.3%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.9%
=
Operating Profit
20.4m
/
Revenue
525.4m

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
NO
Photocure ASA
OSE:PHO
1.4B NOK
4%
US
Eli Lilly and Co
NYSE:LLY
775.3B USD
38%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
3%
US
Johnson & Johnson
NYSE:JNJ
373.9B USD
26%
DK
Novo Nordisk A/S
CSE:NOVO B
2.1T DKK
48%
CH
Roche Holding AG
SIX:ROG
228.6B CHF
32%
UK
AstraZeneca PLC
LSE:AZN
174.1B GBP
23%
CH
Novartis AG
SIX:NOVN
196B CHF
32%
US
Merck & Co Inc
NYSE:MRK
219.3B USD
36%
IE
Endo International PLC
LSE:0Y5F
167.6B USD
11%
US
Pfizer Inc
NYSE:PFE
140B USD
25%

Photocure ASA
Glance View

Market Cap
1.5B NOK
Industry
Pharmaceuticals

Photocure ASA delivers transformative solutions to improve the lives of bladder cancer patients. The company is headquartered in Oslo, Oslo. The company went IPO on 2000-05-29. The company operates in the field of photodynamic diagnosis, cosmetics and treatment of acne, bladder cancer, colon cancer, as well as human papilloma virus (HPV) and precancerous lesions of the cervix. The Company’s activities comprise research, development and commercialization of pipeline projects within two segments: Cancer and Dermatology. Its brand portfolio includes: Hexvix and Cysview, for detection and management of bladder cancer; Visonac, for acne treatment; Cevira, used in HPV and precancerous lesions of the cervix treatment; and Lumacan, applied in colorectal cancer treatment. Furthermore, It owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. The firm is a parent of a wholly owned entity, Photocure Inc.

PHO Intrinsic Value
72.77 NOK
Undervaluation 26%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
3.9%
=
Operating Profit
20.4m
/
Revenue
525.4m
What is the Operating Margin of Photocure ASA?

Based on Photocure ASA's most recent financial statements, the company has Operating Margin of 3.9%.

Back to Top